PUBLISHER: Grand View Research | PRODUCT CODE: 1321447
PUBLISHER: Grand View Research | PRODUCT CODE: 1321447
The global orthopedic regenerative surgical products market size is anticipated to reach USD 5.63 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at an attractive CAGR of 4.0% from 2023 to 2030. The primary factors boosting the market growth include the growing older population, easy availability of orthopedic treatments & procedures, and technological advancements. For instance, osteoarthritis, an orthopedic ailment, has been considered the major factor of chronic disability in the geriatric population (aged above 70 years). The product demand was reduced during the COVID-19 pandemic owing to the low volume of patient flow for chronic ailments in hospitals & clinics, abated marketing & sales activities, postponed elective surgeries, social distancing, and lockdown protocols.
For example, Anika Therapeutics notified challenges in patient enrollment for its clinical trials owing to the pandemic, which adversely impacted the company's operating results and revenue. However, the company recovered financial performance and operations as elective surgeries restarted post-pandemic. As per the Centers for Disease Control and Prevention (CDC), approximately 78 million adults in the U.S., or 26% of the population, are projected to be diagnosed with arthritis by 2040. The risk of arthritis increases with age and is found to be more common in females. Another risk factor is obesity. According to the CDC, the prevalence of obesity in the U.S. was estimated to be around 42.4% from 2017 to 2018. Thus, the growing prevalence of orthopedic ailments and the rising aging population & obesity cases are expected to drive market growth. The products used in orthopedic regenerative surgery have a wide range of applications, including gout, joint pain, fibromyalgia, articular defects, osteoarthritis, joint replacement, and trauma.
This is also anticipated to contribute to the growth of the market. Key players in the market are involved in several strategic initiatives, including R&D projects to introduce new regenerative solutions for pain relief from diseases. For instance, in March 2021, Amniox Medical, Inc., received FDA clearance to proceed with a dosing study using its Investigational New Drug (IND) TTAX03- consisting of the umbilical cord and cryopreserved amniotic membrane, to alleviate facet joint osteoarthritis pain. The market participants offer a wide range of orthopedic products; for instance, Zimmer Biomet provides a wide portfolio of synthetic orthopedic regenerative products and allografts, such as the InterGro DBM, PrimaGen Advanced allograft, and PlatFORM bioresorbable bone graft substitute.